PAVmed (NASDAQ: PAVM) is one of 113 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare PAVmed to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, valuation, earnings and risk.
Institutional & Insider Ownership
6.7% of PAVmed shares are owned by institutional investors. Comparatively, 49.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 29.2% of PAVmed shares are owned by insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for PAVmed and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PAVmed presently has a consensus price target of $5.00, indicating a potential upside of 354.55%. As a group, “Surgical & medical instruments” companies have a potential upside of 379.37%. Given PAVmed’s rivals higher probable upside, analysts plainly believe PAVmed has less favorable growth aspects than its rivals.
Earnings & Valuation
This table compares PAVmed and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|PAVmed Competitors||$1.44 billion||$104.34 million||-168.89|
PAVmed’s rivals have higher revenue and earnings than PAVmed. PAVmed is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
PAVmed has a beta of -0.67, meaning that its stock price is 167% less volatile than the S&P 500. Comparatively, PAVmed’s rivals have a beta of 0.81, meaning that their average stock price is 19% less volatile than the S&P 500.
This table compares PAVmed and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
PAVmed rivals beat PAVmed on 7 of the 13 factors compared.
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.